ZVRA insider trading
HealthcareZEVRA THERAPEUTICS, INC. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About ZEVRA THERAPEUTICS, INC.
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 1/2 clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.
Company website: zevra.com
ZVRA insider activity at a glance
FilingIQ has scored 92 insider transactions for ZVRA since Mar 9, 2023. The most recent filing in our index is dated May 11, 2026.
Across the full history, 34 open-market purchases
and 16 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on ZVRA insider trades is 62.0/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest ZVRA Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for ZVRA?
- FilingIQ tracks 92 Form 4 insider transactions for ZVRA (ZEVRA THERAPEUTICS, INC.), covering filings from Mar 9, 2023 onwards. 6 of those were filed in the last 90 days.
- Are ZVRA insiders net buyers or net sellers?
- Across the full Form 4 history for ZVRA, 34 transactions (37%) were open-market purchases and 16 (17%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does ZVRA insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is ZVRA in?
- ZEVRA THERAPEUTICS, INC. (ZVRA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $483.03M.
Methodology & sources
Every ZVRA insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.